Product Description: Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Hirschhaeuser F, et.al. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. 2010 Nov;59(11):1675-84. /[2]Mansoor M. Amiji, et.al. Chapter Two - Innate and adaptive immunity in cancer. Cancer Immunology and Immunotherapy. Academic Press, 2022, Pages 19-61.
CAS Number: 509077-98-9
Molecular Weight: N/A
Compound Purity: 98.56
Research Area: Cancer
Solubility: H2O
Target: CD3
English
Deutsch
